Clene amends loan with Avenue; Oct payment cut to $2M, interest-only period tied to equity raise and ALS NDA progress

Clene Inc.

October 2024 principal payment reduced from $3.33M to $2M.
Interest-only period from Nov-Dec 2024 contingent on raising $10M in equity by Oct 31, 2024; $7M raised in Sep 2024.
If FDA allows ALS NDA submission for CNM-Au8 by Dec 31, 2024, loan amortization extends to June 2025; otherwise full repayment by April 2025.
Warrant exercise price lowered from $16.00 to $4.6014 per share for Avenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.